Brief: Shanghai Fosun Pharma Says Privatisation Of Shanghai Henlius Biotech Will Not Proceed
22/01/2025 11:10
Jan 22 (Reuters) - Shanghai Fosun Pharmaceutical Group
Co Ltd 600196.SS :
* PROPOSED PRIVATISATION OF SHANGHAI HENLIUS BIOTECH WILL
NOT
PROCEED AND LISTING OF H SHARES ON MAIN BOARD OF STOCK EXCHANGE
WILL BE MAINTAINED
* MERGER WAS NOT APPROVED AT H SHAREHOLDERS' CLASS MEETING.
Further company coverage: 600196.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln